Bladder-sparing treatments, including trimodal therapy, should be carefully considered as alternatives to cystectomy in patients with muscle-invasive bladder cancer (MIBC).
That was the key take-home message of Alexandre Zlotta, MD, PhD, of Mount Sinai Hospital and the University of Toronto, who spoke at the Society of Urologic Oncology annual meeting in Phoenix.
In this video, Dr. Zlotta talks to Urology Times about involving MIBC patients in the treatment decision, how to monitor patients undergoing bladder preservation, and the importance of a specialized, multidisciplinary center in a bladder preservation program.
“I think it’s time to realize that there are other options besides cystectomy, and that the other options should at least be discussed and entertained,” Dr. Zlotta said.
Dr. Zlotta is a consultant for Ferring, Sanofi-Aventis, 3D Biopsy, and Sanofi-Pasteur.